Table 5.
Presence of extended spectrum beta-lactamase (ESBL) resistance genes in the first year of life
| Number of subjects# | Presence | Number of subjects* | Presence | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Extended Spectrum Beta-lactamases | W3 | W3 and M12 | W3 and M12 | W3 | W3 to M3 | W3 to M6 | W3 to M12 | W3 to M3 | W3 to M6 | W3 to M12 |
| blaTEM-1b | 9 | 6 | 67% | 2 | 2 | 2 | 1 | 100% | 100% | 50% |
| blaSHV-1 | 8 | 1 | 13% | 2 | 0 | 0 | 0 | 0% | 0% | 0% |
| blaSHV-11 | 3 | 0 | 33% | 1 | 1 | 0 | 0 | 100% | 0% | 0% |
| blaSHV-142 | 1 | 0 | 0% | 1 | 0 | 0 | 0 | 0% | 0% | 0% |
| blaSHV-83 | 1 | 0 | 0% | 1 | 0 | 0 | 0 | 0% | 0% | 0% |
| blaOXA-116 | 1 | 0 | 0% | 1 | 0 | 0 | 0 | 0% | 0% | 0% |
| blaOXA-347 | 2 | 2 | 100% | 1 | 1 | 1 | 1 | 100% | 100% | 100% |
# subjects with stool samples at both week 3 and month 12 (N = 22) *subjects with stool samples at all timepoints (N = 8)